[go: up one dir, main page]

AU7484596A - Combination therapy for the treatment of diabetes and obesity - Google Patents

Combination therapy for the treatment of diabetes and obesity

Info

Publication number
AU7484596A
AU7484596A AU74845/96A AU7484596A AU7484596A AU 7484596 A AU7484596 A AU 7484596A AU 74845/96 A AU74845/96 A AU 74845/96A AU 7484596 A AU7484596 A AU 7484596A AU 7484596 A AU7484596 A AU 7484596A
Authority
AU
Australia
Prior art keywords
obesity
diabetes
treatment
combination therapy
therapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU74845/96A
Other languages
English (en)
Inventor
Roy G. Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9603724.7A external-priority patent/GB9603724D0/en
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of AU7484596A publication Critical patent/AU7484596A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2264—Obesity-gene products, e.g. leptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Obesity (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU74845/96A 1995-11-01 1996-10-31 Combination therapy for the treatment of diabetes and obesity Abandoned AU7484596A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US713895P 1995-11-01 1995-11-01
US007138 1995-11-01
GB9603724 1996-02-22
GBGB9603724.7A GB9603724D0 (en) 1996-02-22 1996-02-22 Combinatyion therapy for the treatment of diabebes and obesity
PCT/US1996/017444 WO1997016189A1 (fr) 1995-11-01 1996-10-31 Traitement combine du diabete et de l'obesite

Publications (1)

Publication Number Publication Date
AU7484596A true AU7484596A (en) 1997-05-22

Family

ID=26308780

Family Applications (1)

Application Number Title Priority Date Filing Date
AU74845/96A Abandoned AU7484596A (en) 1995-11-01 1996-10-31 Combination therapy for the treatment of diabetes and obesity

Country Status (4)

Country Link
EP (1) EP0858340A4 (fr)
JP (1) JPH11515027A (fr)
AU (1) AU7484596A (fr)
WO (1) WO1997016189A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001968A (en) 1994-08-17 1999-12-14 The Rockefeller University OB polypeptides, modified forms and compositions
EP0784982A3 (fr) * 1996-01-19 1999-08-18 Eli Lilly And Company Préparation des protéines contre l'obésité
CA2263826A1 (fr) * 1996-08-30 1998-03-05 Amgen Inc. Methodes pour accroitre la sensibilite d'un individu a la proteine ob par accroissement de l'affinite du recepteur de la proteine ob
WO1998018481A1 (fr) * 1996-10-31 1998-05-07 Merck & Co., Inc. Therapie par combinaison d'agents pour le traitement du diabete et de l'obesite
EP0920864A1 (fr) * 1997-12-03 1999-06-09 Pfizer Products Inc. Thérapie de combinaison comprenant un beta-3 agoniste spécifique et un agent anorexigéne
KR20010102198A (ko) * 1999-02-16 2001-11-15 후루타 타케시 치환 아세틸피리딘 유도체 및 그를 이용하는 광학활성 β3작용제 중간체의 제조 방법
JP2004331500A (ja) * 2001-02-16 2004-11-25 Dainippon Pharmaceut Co Ltd 血中濃度制御製剤
EP1454899A1 (fr) * 2001-10-17 2004-09-08 Kaneka Corporation Procede de preparation de derives de (s)-alpha-halomethylpyridine-methanol
ATE486842T1 (de) 2002-03-12 2010-11-15 Merck Sharp & Dohme Substituierte amide
GB0718415D0 (en) 2007-09-20 2007-10-31 Glaxo Group Ltd Compounds

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5451677A (en) * 1993-02-09 1995-09-19 Merck & Co., Inc. Substituted phenyl sulfonamides as selective β 3 agonists for the treatment of diabetes and obesity
IL113410A (en) * 1994-04-26 1999-11-30 Merck & Co Inc Substituted sulfonamides having an asymmetric center and pharmaceutical compositions containing them
US5561142A (en) * 1994-04-26 1996-10-01 Merck & Co., Inc. Substituted sulfonamides as selective β3 agonists for the treatment of diabetes and obesity
EP0920864A1 (fr) * 1997-12-03 1999-06-09 Pfizer Products Inc. Thérapie de combinaison comprenant un beta-3 agoniste spécifique et un agent anorexigéne

Also Published As

Publication number Publication date
EP0858340A1 (fr) 1998-08-19
WO1997016189A1 (fr) 1997-05-09
EP0858340A4 (fr) 1999-12-29
JPH11515027A (ja) 1999-12-21

Similar Documents

Publication Publication Date Title
AU7772794A (en) Treatment of obesity
AU7545594A (en) Implantable device for the treatment of aedemas
AU6913796A (en) Patient treatment apparatus
AU4620789A (en) Treatment of obesity
AU4714393A (en) Use of 1,3-dicyclopropymethyl-8-amino-xanthine for the treatment and prevention of type ii diabetes mellitus and obesity
GB9619331D0 (en) Selective ›3 agonists for the treatment of diabetes and obesity
AU1372897A (en) 2-amino-heterocycles and therapeutic uses therefor
GB9618934D0 (en) Inositol phosphoglycans for therapeutic use in the treatment of diabetes and obesity
AU6160594A (en) Diabetes prevention and treatment
AU7484596A (en) Combination therapy for the treatment of diabetes and obesity
AU7105498A (en) Combination therapy for the prevention and treatment of osteoporosis
EP0969852A4 (fr) Therapie par combinaison d'agents pour le traitement du diabete et de l'obesite
AU7529796A (en) S-nitroso-hemoglobin and therapeutic uses thereof
GB2303303B (en) Medical treatment
AU4107797A (en) Compounds for the treatment and prevention of diabetes
EP0724842A3 (fr) Préparation pour le traitement de l'obésité
AUPO108596A0 (en) Treatment of obesity
AU5754996A (en) Agent for the treatment of radiation injuries
AU1587295A (en) The treatment of gaseous substances
GB9711042D0 (en) Combination therapy for the treatment of diabetes and obesity
AUPM615094A0 (en) Methods for the prophylactic and therapeutic treatment of diabetes and prediabetic conditions
GB9603724D0 (en) Combinatyion therapy for the treatment of diabebes and obesity
AU4124497A (en) Treatment of diabetes
AU3429697A (en) Treatment of obesity
GB2304046B (en) Diabetes therapy